A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
Robert S. Busch, MD, FACE; Javier Morales, MD, FACP, FACE; Lucia M. Novak, MSN, ANP-BC, BC-ADM
Release Date: April 30, 2024
Expiration Date: April 30, 2025
Activity Overview
Despite advances in diabetes care, many patients with type 2 diabetes (T2D) frequently struggle to attain the recommended glycemic targets. The difficulty in achieving optimal glycemic control through insulin therapy can be attributed to the complex task of aligning the dosage and timing of daily insulin injections with the individual’s physiological needs. Once-weekly insulin products are substantially shifting the T2D treatment paradigm, and technological advances including continuous glucose monitoring, connected insulin pens, insulin pumps, automated insulin delivery algorithms, and mobile apps need to be appropriately integrated to better manage patients on insulin therapy.
This online, on-demand archive features three expert clinicians discussing the state-of-the-art treatment of T2D. It is designed to equip clinicians with evidence-based knowledge of long-acting basal insulin therapies and increase their confidence as they integrate novel technologies to optimize T2D management.
This educational activity is an archive of the live symposium held on April 19, 2024.
Target Audience
This educational activity is directed toward internists, nurse practitioners, registered nurses, physician assistants, and other health care professionals involved in the care of patients with T2D.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify clinically meaningful differences between currently available and ultra–long-acting basal insulin therapies
- Integrate ultra–long-acting basal insulin analogs into future T2D treatment paradigms based on the most recent safety and efficacy data
- Evaluate differences and best uses for continuous glucose monitoring, insulin pumps, smart pens, and mobile apps
- Incorporate novel technologies for T2D into disease management plans
Robert S. Busch, MD, FACE
Director, Clinical Research
Albany Med Health System
Albany, NY
Disclosures: Speakers’ Bureau: Amylin, Boehringer Ingelheim, Daiichi-Sankyo, Janssen, Merck, New York State Office of Professional Medical Conduct, Novo Nordisk, Sanofi-Aventis, Takeda.
Javier Morales, MD, FACP, FACE
Vice President
Principal Clinical Trials Investigator
Advanced Internal Medicine Group
Associate Clinical Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hofstra University
Hempstead, NY
Disclosures: Consultant: Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk; Speakers’ Bureau: Amgen, AS Pharma.
Lucia M. Novak, MSN, ANP-BC, BC-ADM
Board-Certified Nurse Practitioner
Adult Health and Advanced Diabetes Management
President and Founder
Diabesity, LLC
North Bethesda, MD
Disclosures: Consultant: Abbott Diabetes Care, Nestlé Health Science, Novo Nordisk; Speakers’ Bureau: Abbott Diabetes Care, Novo Nordisk, Sanofi; Other: advisory board: Ascensia Diabetes Care, Boehringer Ingelheim, Medtronic, Novo Nordisk.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Continuous Glucose Monitoring (CGM) ADA Guidance on Insulin Delivery Systems
Benefits of Continuous Glucose Monitoring (CGM)
Professional Continuous Glucose Monitoring (CGM) Devices Comparison Chart
Continuous Glucose Monitoring (CGM) Resources from ADA and ADCES
Understanding and Acting on Continuous Glucose Monitoring (CGM) Data